Howard Colman
Huntsman Cancer Institute · University of Utah
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Howard Colman as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 16:05 UTC. Open this list on ClinicalTrials.gov
- Ph1/Ph2NCT06194929 · Defactinib and Avutometinib, With or Without Encorafenib, for the Treatment of Patients With Brain Metastases From Cutaneous MelanomaUniversity of Utah · recruiting · Cutaneous Melanoma, Brain Metastases · principal investigator
- Ph1NCT05879367 · Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma or AstrocytomaOrbus Therapeutics, Inc. · recruiting · Glioblastoma, IDH-wildtype, Glioblastoma, Glioblastoma Multiforme · principal investigator
- Ph1NCT05169944 · Magrolimab in Children and Adults With Recurrent or Progressive Malignant Brain TumorsUniversity of California, San Francisco · completed · Brain Cancer, Malignant Brain Tumor, Recurrent Brain Tumor · study chair
- Ph1NCT00813566 · Multi-Tracer PET Assessment of Primary Brain TumorsUniversity of Utah · completed · Brain Tumors, Cancer · study chair
Grants
NIH projects from RePORTER, fetched 2026-11-11 16:05 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Effects of combined FAK inhibition with MAPK blockade in brain metastases from cutaneous melanomaR01CA300362 · NCI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · fiscal years 2026 · $634,900 awarded in 2026Same name and institution; not confirmed by an ID
- Protocol Review and Monitoring SystemP30CA042014 · NCI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · fiscal years 2026 · $269,453 awarded in 2026Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 16:05 UTC. The ranking covers the 200 most relevant of 30 PubMed records, and a shared surname and initials can bring in a namesake. All 30 on PubMed
- A randomized trial of bevacizumab for newly diagnosed glioblastoma.N Engl J Med · 20142,246 citationsRCR 69.8
- 1,171 citationsRCR 43.0
- 513 citationsRCR 15.2
- A first-in-human phase 0 clinical study of RNA interference-based spherical nucleic acids in patients with recurrent glioblastoma.Sci Transl Med · 2021276 citationsRCR 17.1
- Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial.Nat Med · 2023275 citationsRCR 24.2
- Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent Glioblastoma.Clin Cancer Res · 2021236 citationsRCR 12.8
- Buparlisib in Patients With Recurrent Glioblastoma Harboring Phosphatidylinositol 3-Kinase Pathway Activation: An Open-Label, Multicenter, Multi-Arm, Phase II Trial.J Clin Oncol · 2019146 citationsRCR 5.1
- A multicenter phase II trial of intrathecal topotecan in patients with meningeal malignancies.Neuro Oncol · 2008103 citationsRCR 2.6
- Phase II study of carboplatin and erlotinib (Tarceva, OSI-774) in patients with recurrent glioblastoma.J Neurooncol · 200889 citationsRCR 2.0
- Validation of postoperative residual contrast-enhancing tumor volume as an independent prognostic factor for overall survival in newly diagnosed glioblastoma.Neuro Oncol · 201878 citationsRCR 3.3